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Background: One of the pressing concerns in health care today is the slow rate at which promising interventions,
supported by research evidence, move into clinical practice. One potential way to speed this process is to conduct
hybrid studies that simultaneously combine the collection of effectiveness and implementation relevant data. This
paper presents implementation relevant data collected during a randomized effectiveness trial of an abstinence
incentive intervention conducted in substance use disorders treatment clinics at two Veterans Health Administration
(VHA) medical centers.
Methods: Participants included patients entering substance use disorders treatment with diagnoses of alcohol
dependence and/or stimulant dependence that enrolled in the randomized trial, were assigned to the intervention
arm, and completed a post intervention survey (n = 147). All staff and leadership from the participating clinics were
eligible to participate. A descriptive process evaluation was used, focused on participant perceptions and contextual/
feasibility issues. Data collection was guided by the RE-AIM and PARIHS implementation frameworks. Data collection
methods included chart review, intervention cost tracking, patient and staff surveys, and qualitative interviews with staff
and administrators.
Results: Results indicated that patients, staff and administrators held generally positive attitudes toward the incentive
intervention. However, staff and administrators identified substantial barriers to routine implementation. Despite the
documented low cost and modest staff time required for implementation of the intervention, securing funding for the
incentives and freeing up any staff time for intervention administration were identified as primary barriers.
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Conclusions: Recommendations to facilitate implementation are presented. Recommendations include: 1) solicit
explicit support from the highest levels of the organization through, for example, performance measures or clinical
practice guideline recommendations; 2) adopt the intervention incrementally starting within a specific treatment track
or clinic to reduce staff and funding burden until local evidence of effectiveness and feasibility is available to support
spread; and 3) educate staff about the process, goals, and value/effectiveness of the intervention and engage them in
implementation planning from the start to enhance investment in the intervention.
Keywords: Substance use disorders treatment, Abstinence incentive intervention, Implementation, Process evaluation,
Hybrid designIntroduction
One of the most pressing concerns in healthcare today is
the slow rate at which promising clinical interventions,
supported by research evidence, move into clinical prac-
tice [1-6]. While effectiveness trials are a step in the re-
search pipeline designed to determine whether promising
clinical interventions work when tested in “real world” set-
tings, the results of such trials generally do not provide cli-
nicians, administrators, or quality improvement specialists
with the information that they will need to successfully
implement the new practice in their clinic or hospital
[7-10]. This is the role of implementation trials which at-
tempt to develop successful strategies for implementing
new, effective practices, which then can be disseminated/
spread to other clinical settings [8,11].
Unfortunately, the timeline from a promising efficacy
trial, through effectiveness and implementation trials, and
finally to dissemination can be measured in multiple years
if not decades and adds to the slow rate of routine uptake
of promising clinical interventions [4,12-14]. Methods to
speed this process are needed. One recently proposed
method is to integrate effectiveness and implementation
study methods using a hybrid design [15]. Curran and col-
leagues propose three hybrid types varying in the degree to
which they focus on effectiveness data versus implementa-
tion data (See Table 1). The Hybrid Type I encourages re-
searchers to initiate the study of implementation as early
as possible in a program of research; more specifically, this
design focuses on integrating implementation research intoTable 1 Typology of hybrid designs*
Research questions Hybrid type 1 Hybrid
Primary Effectiveness: Will the clinical








Secondary Implementation: What are the potential
barriers/facilitators to the treatment’s
implementation?
*From Curran, Bauer, Mittman, Pyne & Stetler, [15].efforts primarily focused on collecting effectiveness data.
As described by Curran and colleagues, the additional in-
corporation of process evaluation methods into an effect-
iveness trial design can help explain effectiveness results
while at the same time efficiently informing future imple-
mentation efforts. In contrast to process evaluation, as de-
fined in this study as part of a Hybrid I design, formative
evaluation [9] is used in a Hybrid II or III design to gather
information for monitoring and actively enhancing imple-
mentation during the course of the implementation-
focused aspect of the study.
Traditionally, process evaluations are used when test-
ing complex clinical interventions and involve collect-
ing data from patients and providers to assess issues
such as whether the clinical intervention was delivered
as designed, whether the patients received the planned
“dose” of the clinical intervention, and whether pro-
viders maintained fidelity to the clinical intervention
protocol [16-18]. Implementation questions in Hybrid
Type I studies instead focus more prominently on bar-
riers and facilitators to uptake/adoption efforts, feasibil-
ity of the clinical intervention, acceptability of the
clinical intervention to providers and patients, and on
identifying tools and training that would assist with
high fidelity implementation. Therefore, information is
collected not only from patients and providers but from
clinical and organizational leaders that would be re-
sponsible for guiding implementation of the clinical
intervention.type 2 Hybrid type 3
eness: Will the clinical
nt work in this setting/with
tients?
Implementation: Which method works






Effectiveness: Is a clinical treatment
effective in this setting/with these
patients?
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combining data collected through qualitative methods
such as interviews, focus groups, and field notes with
data collected through quantitative methods such as sur-
veys and administrative data. While there has been a call
for hybrid studies integrating quantitative effectiveness
data with quantitative and qualitative implementation-
focused process evaluation data, there are few published
protocols documenting the design, execution, and results
of such trials. This paper describes an implementation-
focused process evaluation that was tied to a random-
ized, controlled effectiveness trial of an abstinence incentive
intervention for substance use disorders [19]. The current
paper reports how the process evaluation was developed
and carried out, results of the evaluation, and discussion




This study was conducted at two VHA medical centers.
At one medical center, participants were recruited from
the outpatient substance use disorders treatment clinic
and a dual diagnosis partial hospitalization clinic. At the
second medical center, participants were recruited from
the outpatient substance use disorders treatment clinic.
As approved by the institutional review boards at each
facility, patient participants completed written informed
consent and staff participants completed verbal informed
consent. Patients were eligible to participate if they were
beginning a new treatment episode for alcohol depend-
ence and/or stimulant dependence. All clinical staff and
clinic leaders were eligible to participate. Clinical staff
was recruited through announcements at clinical staff
meetings and emails. Clinic leaders were recruited
through email and telephone contacts. During the study,
patients were randomized to receive usual care sub-
stance use disorders treatment with or without financial
abstinence incentives. All participants were scheduled to
submit alcohol breath and drug urine screens twice per
week for eight weeks. Those in the incentive condition
could draw from a prize bowl when they submitted
negative breathalyzer and urine screens. The prize bowl
contained slips that either said “Good Job” but had no
monetary value or were worth $1, $20, or $80 vouchers,
which could be redeemed at a VHA cafeteria or gift
shop. The number of drawings earned increased with
each consecutive week of abstinence.
Process evaluation plan
The initial step in development of the process evaluation
plan was the selection of an implementation framework
that would guide the questions asked. For the purpose of
this study, our team selected the RE-AIM framework[20-22] as the primary guide supplemented with ele-
ments from the Promoting Action on Research Imple-
mentation in Health Services (PARIHS) framework
[23-25]. RE-AIM is an acronym for reach, effectiveness,
adoption, implementation and maintenance. Briefly,
Reach refers to the percentage of eligible patients that
agree to the clinical intervention. Effectiveness evaluates
whether the clinical intervention achieved the desired
patient outcomes. Adoption refers to the decision of the
leadership and staff at the targeted settings to implement
the clinical intervention. Implementation refers to whether
the clinical intervention is implemented with high fidelity
and consistency. Implementation also includes an assess-
ment of the cost of the intervention. Finally, Maintenance
refers to whether the clinical intervention is sustained
after implementation support is withdrawn. The frame-
work proposes that each of these elements is essential to
consider when planning an implementation strategy or an
implementation evaluation. According to Kessler and col-
leagues [26], RE-AIM has been used to “plan, evaluate and
review a variety of health promotion and disease manage-
ment interventions” and “over 150 published studies…
state they are using the RE-AIM model.” However, many
of these studies did not include a comprehensive evalu-
ation of all framework elements. See Kessler and col-
leagues’ paper [26] on employing the RE-AIM framework
for an excellent description of general questions prompted
by each element of the model.
Guided by the framework, we developed a series of
questions that would provide valuable information for
future implementation efforts. (See Table 2, which also
includes measurement tools discussed below.) Because
our purpose was to collect information during an effect-
iveness trial to inform future implementation rather than
to evaluate an actual implementation effort, our ques-
tions are slightly different from those recommended by
Kessler [26].
The PARIHS framework proposes that successful im-
plementation is a function of evidence, context and fa-
cilitation. For our purposes, we chose to evaluate the
elements of evidence and context as follows:
Evidence: In the PARIHS framework, this element
refers to the strength and extent of evidence for clinical
practice changes and includes research evidence,
evidence from clinical practice, perceived patient
needs and preferences, and local data/information.
The RE-AIM framework lacks a component specifically
addressing clinicians’ assessments of the evidence
supporting an innovation.
Context: In the PARIHS framework, this element refers
to “the environment or setting in which people receive
healthcare services” or, in the context of getting
research evidence into practice, ‘the environment or
Table 2 Implementation framework elements guide process evaluation questions and tools
Element Questions Data sources Tools
RE-AIM
Reach What percentage of patients approached
agree to participate in the intervention?
Recruitment rates. Patient screening database.
Do those that agree to participate differ
systematically from those that do not?
Demographics of those agreeing
vs. those refusing participation.
Chart review of administrative data.
What do patients like and dislike about
the intervention?
Perceptions of patients. Post-intervention patient surveys.
Effectivenessa What is the effect of the intervention on
patient outcomes?
Main study outcomes comparing
control to intervention patients.
Rates of negative urine screens.
Study retention.
Adoption What are the greatest barriers to adopting
the intervention?
Perceptions of staff and leadership. Research team observational log.
Post-intervention staff interviews.
What supports will need to be in place for
clinics to adopt the intervention?
Post-intervention leadership interviews.
Implementation What supports need to be in place to ensure
consistent delivery of the intervention?
Perceptions of staff and leadership. Post-intervention staff interviews.
Post-intervention leadership interviews.
What tools will be needed to deliver the
intervention consistently?
Perceptions of research staff Training protocols for research staff.
What does the intervention cost? Cost data. Records of incentives awarded, costs
of intervention supplies and staff time
required.
Maintenance What resources will be needed to maintain
the intervention in the long run?
Perceptions of leadership. Research team observational log.
Post-intervention leadership interviews.
What adaptations will need to be made to
integrate the intervention into regular practice?
PARIHS
Evidence What are staff perceptions of the evidence
supporting the intervention?
Perceptions of staff and leadership. Organizational Readiness to Change
Assessment (ORCA) Evidence Scales
What are their attitudes toward the intervention?
Does the intervention fit with their current
clinical practice?
Does the intervention meet a perceived
need of their patients?
Context What are the characteristics of the culture in the clinic? Organizational readiness measure
collected from staff and leadership.
Organizational Readiness to Change
Assessment (ORCA) Context Scales
What are the characteristics of the leadership of the clinic?
What resources are available to the clinic?
aEffectiveness outcomes are reported elsewhere [19].
Hagedorn et al. Addiction Science & Clinical Practice 2014, 9:12 Page 4 of 15
http://www.ascpjournal.org/content/9/1/12setting in which the proposed change is to be
implemented” [23]. Given the importance of context in
a number of implementation frameworks e.g., [27-29]
and the fact that RE-AIM does not specifically address
context, we felt that assessing this element would add
important information to our process evaluation.
Specifically, it could enhance our interpretations of
setting-related barriers and facilitators to this innovation.
PARIHS’s facilitation element is defined as an appointed
role wherein an individual helps and enables others to
change [23]. Evaluation of facilitation was not felt to be
relevant to this study as the research staff administered
the study’s clinical intervention and were not providing
such help or support to assist clinical staff with real-timeimplementation. However, information gained from asses-
sing the RE-AIM framework, as well as PARIHS’ evidence
and context elements, was expected to provide sufficient
information to inform development of future facilitation
strategies.
Data collection tools
Data tools included pre-existing scales, surveys and in-
terviews designed specifically for this study, observa-
tional notes, data forms completed by research staff, and
chart reviews to collect administrative data (Table 2).
Chart review data
In order to track Reach of the intervention, a screen-
ing database was maintained which contained basic
Table 3 Items added to organizational readiness to
change scale to assess providers personal preferences
and intentions
Construct Item
Preferences • If monetary rewards can help patients to
achieve abstinence, I support it.
• Giving patients monetary rewards for staying
abstinent or attending treatment is wrong.
(reverse coded)
• Patients who really want to stay abstinent
shouldn’t need monetary rewards. (reverse coded)
• We need to use every possible tool, including
monetary rewards, to help patients succeed
in treatment.
• Giving patients monetary rewards for abstinence or
treatment attendance is an inappropriate use of
VHA funds. (reverse coded)
• Giving patients monetary rewards will recognize
their achievements and give them a sense
of accomplishment.
Intentions • I would like to see the use of incentive interventions
in this clinic.
• There are specific plans in place to implement an
incentive intervention in this clinic.
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that was approached regarding participation in the study.
This information was used to determine the percentage of
patients approached that agreed to participate and to
compare basic demographic and diagnostic characteristics
of those agreeing and declining participation.
Cost records
One consideration in regards to Implementation of a
new intervention is the cost associated with the inter-
vention. A standardized computer data entry screen was
used to document the amount of time required for each
participant intervention appointment and the monetary
value of any vouchers earned. Staff time was converted
into costs using three different wage rates plus a 30%
fringe rate. Average wage rates were calculated for: 1) li-
censed practical nurses, which clinic leadership indicated
would be the most likely staff position to administer the
intervention if one person were assigned to administer it
to all patients, 2) the actual research staff that adminis-
tered the intervention for the study (Bachelor’s level re-
search assistants), and 3) licensed clinical social workers,
which clinic leadership indicated would be the most
likely staff position to administer the intervention if each
case manager were assigned to administer it to their
own patients.
Patient surveys
To collect information that could improve the Reach of
the incentive intervention, participating patients com-
pleted post-intervention surveys at the end of the eight
week intervention period. The survey queried patients
about what they liked and did not like about the inter-
vention, any interactions they had with their clinical
treatment team related to their participation in the inter-
vention, and their thoughts on potential modifications to
the incentive intervention.
The Organizational Readiness to Change Assessment
(ORCA)
The ORCA is a 77-item scale designed to measure ele-
ments of the PARIHS framework [30,31]. Items pertaining
to the evidence and context elements were administered.
The evidence scale both assesses the respondents’ opin-
ions regarding support for the proposed intervention
based on research evidence, clinical experience and pa-
tient preferences, as well as their perception of colleagues’
related support. Because preliminary discussions with staff
indicated that incentive interventions can be controversial,
we added an additional eight items to assess personal
opinions and intentions regarding incentive interventions
(see Table 3). The context scale contains six subscales:
leadership culture, staff culture, leadership practices,
measurement (e.g., leadership feedback), readiness tochange among opinion leaders and resources to support
general practice changes.
ORCA surveys were handed out at clinical staff team
meetings after all patient participants had completed the
intervention phase of the trial. No identifying informa-
tion was collected so that completion of the assessment
was voluntary and anonymous.
Staff interviews
To collect information on Adoption, Implementation and
Maintenance, after all patient participants had completed
the intervention phase of the trial, staff members that
agreed to be interviewed were asked their opinions regard-
ing the intervention and how it impacted the clinic, their
interactions with their patients, and their workload. They
were also asked about barriers and facilitators to maintain-
ing the intervention as part of standard clinical care. No
identifying information was collected during the inter-
views other than the staff members’ role in the clinic.
Leadership interviews
To collect information on Adoption, Implementation and
Maintenance, after all patient participants had completed
the intervention phase of the trial, clinic leaders were
asked about their plans to continue the incentive interven-
tion in their clinic, perceived incentives for maintaining
the intervention, barriers and facilitators to maintaining
the interventions, and types of support that would be most
helpful in adopting and maintaining the intervention.
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To supplement information regarding Adoption, Imple-
mentation and Maintenance, a shared research staff ob-
servational log was created to document interactions with
clinical staff and patients that provided information on
their expressed attitudes toward the intervention and
their comments on perceived barriers and facilitators
to adoption, implementation, and maintenance of the
intervention. The idea behind the log was that opinions
might surface during day-to-day interactions with re-
search staff that might not be readily reported when
utilizing more formal data collection methods such as
surveys and interviews.Data analysis
Descriptive quantitative results are reported in percent-
ages. Chi-square tests, and Z or t-tests were used to com-
pare distributions, proportions and means of different
subgroups. Qualitative information from open-ended sur-
vey questions, interviews, and research log entries were
transcribed and analyzed using common coding tech-
niques for qualitative data [32]. The principal investigator
(HH) and the research coordinator (E. Marut) independ-
ently reviewed the transcripts and developed initial coding
lists. A deductive analysis approach was used during
the development of the initial coding list to focus codes
on pre-determined domains of interest. This included
attitudes toward the intervention, barriers to and faci-
litators of implementation, and recommendations for
improvement of the intervention. Following develop-
ment and refinement of the initial coding list, each
transcript was coded, with additional inductive codes
added that identified important themes not represented
by the pre-determined domains. Consensus meetings
were held for review of consistency in coding. Inconsist-
encies were resolved through mutual discussion and
agreement.Figure 1 Participant recruitment.Results
Patient screening data
Figure 1 provides recruitment information including per-
cent of contacted patients that participated and declined
and reasons for declining. Table 4 provides demograph-
ics for those that declined participation and those that
agreed to a baseline appointment. African Americans and
patients with stimulant dependence diagnoses agreed to
participate at higher rates than patients in other demo-
graphic and diagnostic categories.
Costs
Table 5 presents cost information. Most substance use
disorders clinics have a breathalyzer unit available so the
cost of the unit was not included as a cost of the inter-
vention. However, if a clinic needs to purchase a breath-
alyzer, one can be purchased for less than $500. The
system to track appointment length indicated that mean
appointment length was 7.0 minutes (SD = 4.5). Costs
were assessed based on 15 minute appointments because
the minimum appointment scheduling time in the VHA
is 15 minutes and 15 minutes per appointment would
have allowed sufficient time for 96% of all appointments.
Staff costs were multiplied by the 16 scheduled appoint-
ments rather than the number of appointments actually
attended. This accounted for staff time spent document-
ing no-shows and contacting patients to reschedule.
Patient surveys
The post-intervention survey was completed by 147 of
the 165 patients (89%) that were assigned to the incentive
intervention. When asked what they liked about partici-
pating in the intervention, 94% of participants gave a
response. When broadly categorized, the top response
categories were “liked earning the rewards” (44.3%), “the
intervention supported abstinence” (37.0%), and “liked
working with the research staff” (22.4%). One partici-
pant summarized her experience in the following way:
Table 4 Demographic characteristics of patients that declined participation and patients that scheduled baseline
appointment
Characteristic Declined participation Scheduled
N = 182 (33.03%) N = 369 (66.97%)
Male 178 (97.80%) 361 (97.83%)
Female 4 (2.20%) 8 (2.17%)
African American 34 (18.68%) 136 (36.68%)
White 124 (68.13%) 194 (52.57%)
Other non-white 4 (2.20%) 10 (2.71%)
Age in years, median 52.5 50
Psychiatric Diagnoses
Depression 59 (32.42%) 131 (35.50%)
PTSD 29 (15.93%) 46 (12.47%)
Other anxiety, mood, or psychotic diagnosis 37 (20.33%) 53 (14.36%)
Substance Dependence Diagnoses
Alcohol Dependence 172 (94.51%) 307 (83.20%)
Stimulant Dependence 32 (17.58%) 156 (42.28%)
Other Substance Dependence 18 (9.90%) 33 (8.94%)
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your short-comings. It is focused on positives with the
incentives. It helped me to stay sober and helped me
to commit to not drinking. I really liked it.”
When asked what they did not like about participating
in the intervention, 78% of participants stated “nothing.”
The most frequent category, reported by 10% of partici-
pants, were complaints about the reward system, e.g., the
rewards were not big enough. Participants stated that:
“I didn’t like the reward scale, the odds of not winning.”
“Those “Good Job” things, I didn’t like picking those.”Table 5 Costs of the intervention
Expense item Cost (Mean)
Incentive Vouchers $103.07




Staff Costs LPNb = $102.72
(16 appointments × 15 minutes each) BAc = $125.60
LCSWd = $152.00
Total Cost per Patient $266.93 - $316.21
a11.6 =mean number of intervention appointments attended.
bLicensed Practical Nurse: $41,101 base + 30% fringe.
cBachelor’s level research assistant: $50,275 base + 30% fringe.
dLicensed Clinical Social Worker: $60,827 base + 30% fringe.“Dang it, (name of other participant) won $80 and not
me!”
Other responses included “the appointments were in-
convenient” (8%) and “did not like the testing procedures”
(3%).
When asked to rate the impact of the incentive interven-
tion on their personal treatment outcomes, 81 (55.1%) par-
ticipants rated the impact as highly positive, 47 (32.0%)
participants rated the impact as somewhat positive and 19
(12.9%) participants rated the incentives as having no im-
pact on their treatment outcomes. None of the participants
rated the impact of the incentives on their personal treat-
ment outcomes as either somewhat or highly negative.
Only 22.8% of patients reported that someone from
the clinical team had discussed their intervention partici-
pation with them. Of these conversations, the majority
were neutral (63.0%) and involved a clinical staff person
either mentioning the opportunity to be involved in the
study or asking how participation was going. The remain-
der of the conversations were positive (37.0%) with the
clinical team member indicating that it was a good thing
for the patient’s recovery to be involved in the interven-
tion. There were no reports from patients of clinical staff
making negative comments about their intervention par-
ticipation. There were only two instances where a patient
reported that a clinical team member discussed specific
urine and breathalyzer screen results from the interven-
tion with the patient.
Participants indicated that the intervention would have
been more effective if it had been longer (greater than
8 weeks), if the prizes available had been bigger, and if it
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jumbo prizes. The participants indicated that the inter-
vention would have been less effective if it had been
shorter (less than 8 weeks), if the appointments had
been less frequent (less than 2 times per week), and if
the intervention had taken place in a group setting
where patients would know each other’s test results and
reward earnings.
Organizational readiness to change assessment
The ORCA was completed by 13 staff members from each
of the two participating substance use disorders clinics
(Total N = 26/39, 67% response). At the first site, respon-
dents included five social workers, three nurses, two psy-
chiatrists, one psychologist, and two staff members that
did not record their role in the clinic. At the second site,
respondents included five social workers, one nurse, three
psychiatrists, three psychologists, and one staff member
that did not record his/her role in the clinic.
Staff at both sites expressed agreement with the evi-
dence supporting incentive interventions. On a scale of
1 to 5, with 5 representing strong agreement, the mean
evidence scale rating was 3.7 for site one and 3.9 for site
two. Mean scores on the three evidence subscales (re-
search evidence, clinical experience, and patient prefer-
ences) were all above 3.7 for both sites. None of the
differences between sites were significant. On the six
items related to personal opinions regarding incentive
interventions, site one had a significantly lower rating
(M = 3.5) compared to site two (M = 4.2; p = .01) al-
though site one was still in the supportive range (> 3). In
regards to the intentions questions, on the item asking
whether they would like to see an incentive intervention
continue in their clinic, site one had a significantly lower
rating (M = 3.8) than site two (M = 4.5; p = .027) but
both sites were in the supportive range. In looking at
individual scores, site one had three individuals that had
clearly negative opinions regarding the incentive in-
tervention which pulled down the overall score for the
clinic despite the majority of staff expressing support.
When asked if there were any specific plans in place to
continue an incentive intervention in the clinic, the
mean rating for both sites was 2.8 indicating that while
they were supportive of the intervention, they were un-
aware of any clear plans in place to sustain it following
the research study.
Staff at both sites also indicated that their sites had
contexts that were supportive of innovation in general.
The mean context scale rating was 3.6 for site one and
3.3 for site two. Mean scores on five of the six context
subscales (leadership culture, staff culture, leadership
practices, measurement, and opinion leaders) were all
above 3.1 for both sites. None of the differences between
sites were significant. The only context subscale to havenegative mean ratings from both sites was the resource
subscale indicating that staff at both sites did not feel
that they had the financial resources, training, facilities
or staffing necessary to adequately support implementa-
tion of innovations. Site two had a significantly lower
mean rating on resources (M = 2.0) than site one (M =
2.9; p = .01).Staff interviews
Seven interviews were conducted with staff from site
one and two were conducted with staff from site two.
The professional roles of those interviewed included
two nurses, two social workers, one psychologist, one
addiction therapist, and three whose roles were not
identified.
When staff were asked what they liked about having
the incentive intervention in their clinic, the most com-
mon themes to emerge, mentioned by three or more re-
spondents, were that the intervention motivated patients
to continue treatment, the intervention provided the pa-
tients with tangible rewards for success, the intervention
provided the patients with additional support, the inter-
vention provided the staff with objective outcome data,
and that the intervention was a positive/enjoyable ex-
perience for patients. For example, one staff member
summed up her experience with the intervention in the
following way:
“I liked it because it motivated the clients. There was
a possibility for them to win something. Also, praise
goes a long way. They come to (name of treatment
program) beaten down and the incentives provided
them with positive reinforcement.”
When staff was asked what they did not like about hav-
ing the incentive intervention in their clinic, six of nine
responded nothing. Two staff reported a concern that the
intervention focused patients on external rather than in-
ternal motivation for change as exemplified by the follow-
ing quote:
“Sometimes it seemed that the patients enrolled in the
intervention were more superficial in their treatment.
They had to stay sober for the rewards and money,
not for deeper reasons.”
Two staff also reported a concern that the intervention
could trigger gambling behavior.
When asked whether the intervention had any impact
on clinic functioning or atmosphere, the most common
theme, mentioned by five respondents, was that the inter-
vention provided an additional opportunity to support pa-
tients’ recovery, as exemplified in the following quote:
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working together as a team to help the patients. I
think the patients got the sense that, as a clinic, we
were committed to helping them to get and stay
sober. The incentive study helped with that.”
None indicated a negative impact of the intervention.
When asked whether the study intervention had any im-
pact on individual respondents’ workloads, six of nine
respondents stated that there was no impact. Those that
reported an impact reported co-signing incentive inter-
vention appointment notes and having more contact with
patients during the aftercare phase of treatment. All three
agreed that this increased interaction improved treatment
for the patients. As one staff member described it:
“There were a lot of notes to cosign, although it was
always optional. I like to have the information about
who was showing up for intervention appointments
and who was testing positive and negative.”
When asked if the intervention influenced their inter-
actions with their patients, five of nine respondents
indicated that it did not. Those that did indicate an in-
fluence reported talking with their patients about their
study earnings and adding ongoing participation in the
intervention to patients’ aftercare recovery plans.
When asked if they would like to see the intervention
continue in the clinic after the research study ended, seven
of the nine respondents said yes. The remaining two
stated that their opinion would depend on the results of
the study. When asked about barriers to adopting the
intervention as part of standard clinical treatment, the
most common theme, cited by six respondents, was cost.
An additional barrier mentioned by three respondents was
allocating staff time to administer the intervention. As
summed up by one staff person:
“The time commitment would be a barrier. You need
staff that would be in charge of this. The expense
would also be a barrier. I see the lab costs as being
the most expensive cost. Sending confirmations to the
lab is very expensive but I think it’s really important
that we do that.”
When asked what would make it easier to adopt the
intervention as part of standard clinical treatment,
themes reported by three or more respondents were
dedicated staff and soliciting buy-in from all staff in the
clinic prior to implementation to decrease resistance.
For example, one staff person stated:
“Everybody needs to be on the same team. There needs
to be staff buy-in from everyone involved. Anotherthing is that it should not be considered a secondary
part of treatment. It should be an integral part.”
Leadership interviews
All three leaders of the participating clinics indicated
that they were interested in implementing an incentive
intervention but that it was not currently feasible due to
significant barriers. In the outpatient substance use dis-
orders clinics, the main perceived barriers were as fol-
lows: staff were already stretched beyond capacity, the
need to either gain additional staff or reallocate staff
time from other priorities, and the need to identify a
funding source for both the incentives and the rapid
urine test cups. As one of the leaders put it:
“The biggest barrier is that I would have to pull staff
from other tasks in order to do it. There are only so
many staff members and something else would have
to give.”
In the dual diagnosis partial hospitalization clinic, the
main barrier cited was that their program was primarily
group based and therefore, they would need expert con-
sultation to determine the best way to incorporate the
intervention into the group setting. Staff time was also a
concern for this clinic.
All of the leaders indicated that there were significant
incentives for pursing implementation. The leaders in the
substance use disorder treatment clinics noted that the
intervention appeared to improve treatment retention and
that this improved their clinics’ functioning on a VHA
substance use disorders treatment continuity of care per-
formance measure that was monitored by national leader-
ship as demonstrated by the following quote:
“For me, the continuity of care is a big incentive. It
(the intervention) keeps the patients engaged in
treatment and coming in for appointments.”
The leader of the dual diagnosis clinic noted that incen-
tive interventions are an empirically supported treatment
and that empirically supported treatments generally, and
incentive interventions specifically, were strongly sup-
ported by national leadership. When asked what types of
assistance would be most beneficial to support implemen-
tation, suggestions included educating staff and facility
leadership regarding the evidence for incentive interven-
tions and expert consultation in designing an incentive
intervention that would fit into the current practices of
the clinic.
Research observational log
Research staff recorded over 150 contacts with clinical
staff in the log. The vast majority of recorded contacts
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intervention both through assisting the research staff
with recruitment of participants and with maintaining
contact with participants during enrollment in the study.
Clinical staff comments indicated the intervention was
useful to their work with patients by allowing regular
monitoring of urine screen results and keeping patients
connected to aftercare. When one of the research assis-
tants approached a staff member about recruitment of a
specific patient, the staff member spontaneously replied:
“I really appreciate how the study keeps the patients
coming back to the clinic. It helps keep them
connected to aftercare after they complete their
intensive program. It gives them another long term
connection and support.”
The research log also prompted the research staff
to identify and act on suggestions from clinicians to
enhance clinician involvement with the intervention. For
example, staff at both facilities requested that they re-
ceive regular updates on participants’ progress in the
incentive intervention. Research staff worked with the
clinicians to identify the best way to achieve this goal at
each facility. A second suggestion that came from clin-
ical staff was that the patient’s case manager should be
invited to the final intervention appointment in order to
celebrate this achievement with their patient; however
when this was offered, staff attended infrequently.
As stated above, the vast majority of recorded interac-
tions were positive but there were barriers and negative
responses to the intervention recorded as well. The
major barrier to integrating the intervention into clinic
processes at one facility was that the clinicians did not
want to rely on the rapid urine test cups for clinical test-
ing of substance use. They preferred to send samples
directly to the laboratory. This created a great incon-
venience for patients who were often asked to submit
two urine samples (one for research and one for clinical
purposes) within a very short time frame. During the
course of the intervention, several instances arose where
clinical staff required immediate knowledge regarding
whether a patient was under the influence of substances
and sought out research staff to request access to a rapid
test cup, which the research staff readily provided. As
the clinicians gained familiarity with the test cups, they
gained confidence in the rapid test cup results and even-
tually allowed patients to use their research sample as
their clinical sample. An additional complaint was that
some clinicians noted that patients were consistently
attending their research intervention appointments but
skipping their clinical care appointments.
Research staff recorded over 50 interactions with patients
involving spontaneous comments about the intervention inthe research log. The majority of these comments were
positive and related to patients’ perceived benefits of the
intervention. Several patients reported that the inter-
vention was helping them to maintain their sobriety.
Four patients recounted specific instances in which they
were experiencing a craving to use substances and thought
about the incentives they hoped to earn to assist them in
fighting the craving. In one of these cases, the participant
stated while he was picking that he had really wanted to
have a drink the previous weekend but that he did not
want to have his picks reset. He then pulled out a $20
voucher and was so excited that he started to dance
around the office. He stated:
“That reward was so worth not having a drink over
the weekend!”
Several participants also reported that they had recom-
mended participation in the intervention to other patients.
Additional positive comments included appreciating being
able to see their urine test cup results immediately and
that the intervention gave them a documented record of
urine screens that their clinicians could access. Patients
also expressed satisfaction with the wide selection of
items available at the VHA gift shop that could be pur-
chased with their vouchers. The majority of the complaints
about the intervention centered on disappointment with
not drawing the larger vouchers.Discussion
The final step in conducting our process evaluation was
to triangulate the results from the various data sources
to answer the questions that were developed based on
the elements of the selected frameworks (see Table 1)
and to summarize lessons learned (see Table 6).Reach
Screening data indicated that 60% of potential participants
agreed to enroll in the intervention. The most common
reasons for declining to participate related to the time
commitment involved in having to attend appointments
twice per week. This would suggest that the intervention
may be most appropriately targeted to patients that will be
coming to the clinic two or more days per week for other
treatment services so as to reduce trips to the facility
solely for the purpose of the 15 minute intervention ap-
pointment. African American patients and patients with
stimulant dependence diagnoses agreed to participate at
higher rates than patients in other demographic and diag-
nostic categories. The reliability of this observation as well
as its clinical significance would need to be assessed in fu-
ture research. It is clear from the patient survey and re-
search log data that the vast majority of patients that
Table 6 Suggestions to enhance implementation efforts
based on the RE-AIM framework
Reach • Target intervention to patients that will be
attending treatment at least twice per week for
other treatment services.
Effectiveness • Share results of VA and non-VA trials
Adoption • Solicit explicit support from the highest levels of
the organization through, for example, performance
measures or treatment recommendations.
• Identify or create measures of clinic effectiveness
which can be utilized to identify gaps in performance
and monitor the impact of implementation.
• Solicit agreement in advance for designated funding.
• Educate leadership about time commitment related
to the intervention and potential strategies for
integrating the intervention into current practices.
• Adopt incrementally. Start with a specific treatment
track or clinic to reduce staff and funding burden
until local evidence of effectiveness and feasibility is
available to support spread
Implementation • Disseminate information to educate staff about
the process, goals, and value/effectiveness of the
intervention and engage them in planning for the
intervention from the start.
• Provide expert consultation on how to adapt the
intervention for specific clinic environments.
• Train staff on urine test cups and breathalyzer
including sensitivity and specificity of the screen
results.
• Make scripts available for communicating positive
and negative test results to patients.
• Supply a tracking database to ensure consistency
in awarding prize picks.
• Provide a step by step intervention appointment
protocol.
• Facilitate documentation in the electronic health
record.
Maintenance • Ensure all staff is aware of their responsibilities related
to incorporating information from the intervention
into clinical interactions with patients to facilitate
integration into the clinic.
• Consider option of having case managers administer
the intervention to their own patients rather than
having one or two individuals responsible for the
intervention.
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a positive one.Effectiveness
The primary outcomes of this study are reported else-
where [19]. However, in brief, in the alcohol dependent
subgroup, incentive participants submitted significantly
more negative samples (13 vs. 11 samples), were retained
significantly longer (7 vs. 6 weeks), and achieved signifi-
cantly longer median durations of abstinence (16 vs. 9
consecutive visits compared to usual care participants).Intervention effects were non-significant for the stimu-
lant dependent subgroup. While these non-significant re-
sults for the stimulant dependent group were surprising,
we believe these results were related to the characteristics
of the recruited participants, specifically that they ap-
peared to have less serious stimulant dependence com-
pared to samples in several previous significant trials.
Despite the non-significant results of this one trial, we be-
lieve that the extensive literature supporting incentive in-
terventions with stimulant dependent patients supports
implementation e.g., [33-36]; and further the results of this
trial may provide some guidance in selecting patients most
likely to benefit from incentive interventions.
Adoption
Leadership identified some strong rationales for adoption
of incentive programs. They perceived that incentive in-
terventions would be valuable to improve their treat-
ment retention performance ratings. Additionally, they
believed national leadership viewed implementation of
incentive interventions as a priority, and in fact, incen-
tive interventions had been designated by national lead-
ership as an evidence-based practice. The fact that the
clinic leaders both expressed dissatisfaction with their
own clinics’ performance on the treatment retention
performance rating and perceived the incentive inter-
vention as directly addressing this issue appeared to be
the strongest motivator for adopting a change in prac-
tice. Clinic leaders that do not perceive issues with the
effectiveness of their program at baseline may be less
likely to express motivation to adopt practice change.
This highlights the importance of having measures
available to assess clinic effectiveness which can help to
identify gaps in performance and assess the impact of
changes in clinic practices.
However, these strong rationales for adoption could not
override the greatest barrier, which was lack of resources
in the form of staff time and funding for vouchers and
urine testing supplies. Multiple data sources, including the
ORCA, staff interviews, leadership interviews, and the re-
search log, all indicated that lack of resources was the pri-
mary perceived barrier to adoption of the intervention. To
address the perceptions regarding staff time, we can sug-
gest two implementation strategies that may decrease
leadership concerns about staffing burden: providing edu-
cation in advance as regards the amount of time necessary
to administer the incentive intervention (15 minutes or
less per instance); and presenting various options for inte-
grating the intervention into current clinic staffing pat-
terns especially when group sessions are the predominant
modality. While cost of the intervention is traditionally
considered to fall under the Implementation construct of
the RE-AIM framework, we consider cost under the
Adoption construct given the high relevance of funding
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ticular intervention. The mean total cost of the eight week
intervention was $266.93 – $316.21 per patient depending
on the salary rate of the individual administering the inter-
vention. This cost could be reduced by using lower wage
staffing. While a full cost-effectiveness evaluation is be-
yond the scope of this paper, the incentive intervention
was shown to increase participants’ longest duration of
abstinence during treatment [19] which is one of the best
predictors of long-term patient outcomes [37-39]. Olm-
stead and colleagues have published two articles reporting
on the cost-effectiveness of incentive interventions [40,41].
The potential for decreased societal costs related to med-
ical expenses, criminal/legal costs, and lost productivity
would suggest that this is a low price for an intervention
that improves substance use disorders treatment outcomes.
Providing education regarding the low cost and the cost-
effectiveness of the intervention and soliciting agreement
in advance from facility leadership for dedicated funding
appear to be essential to adoption.
It should be noted that adoption of many new evidence-
based practices into an existing clinic milieu will require
additional resources, so such barriers are not unique to in-
centive interventions. Another potential implementation
strategy may be to assist clinic leadership in identifying
current clinic practices that are not evidence-based or that
have been shown to contribute little to treatment out-
comes, e.g., didactic education [42]. The implementation
team and the clinic leadership could then focus on strat-
egies for reallocating existing resources from current non-
evidence based practices to implementation of evidence
based practices not currently available in the clinic.
Clinic leadership also indicated that it would be an
easier “sell” to facility leadership to begin by targeting
the intervention to a small group of patients. This would
offer a way to test the intervention in the clinic and col-
lect local outcome data that could then be used to advo-
cate for sustained funding support for the intervention
at a later date. Starting with a “test” of the intervention
could also lessen staff resistance and allow them to ob-
serve the effectiveness of the intervention in their own
clinic and the impact of the intervention on their work-
load prior to committing to sustained implementation.
Implementation
Once a clinic has made a decision to adopt the incentive
intervention, supports must be in place to ensure that
implementation is carried out with high levels of fidelity
and consistency. The staff and leadership interviews sug-
gested several ways that high quality implementation
could be enhanced. These include: 1) involving staff in
implementation planning to increase knowledge regard-
ing essential intervention elements; 2) providing support
for adapting the intervention to fit the current clinicstructure through expert consultation and recommended
strategies based on common clinic structures; and 3) de-
fining clear roles for all clinical staff related to the inter-
vention so that it would be a clinic-wide initiative rather
than viewed as only the responsibility of specific people.
In addition to these supports, the research log suggested
that it would be beneficial to train all staff on the use of
rapid urine test cups and their specificity and sensitivity
prior to implementation to address concerns about the
reliability of that technology.
Other observations related to implementation tools
that could be used to enhance consistent delivery of this
intervention come from our experience in training the
research staff. Research assistants (RAs) were provided
with training on the accurate use of the rapid urine test
cups and the breathalyzer unit and with scripts for how
to communicate screening results to patients. Addition-
ally, a database was created that tracked the number of
picks that a patient was entitled to at a given appoint-
ment based on their previous record of attendance and
test results. This simplified the work of the RAs and en-
sured the consistency with which the incentives were
distributed. RAs were also provided with a manual that
described the steps of an intervention appointment from
beginning to end. Once an RA had completed their
training and read the manual, they completed a mock
intervention appointment with one of the investigators
(HH, DK) prior to completing intervention appoint-
ments with patients. These same training tools and steps
could be provided to clinical staff to ensure consistent
delivery of the intervention.
Maintenance
In examining Maintenance, we were primarily interested
in adaptations that could be made to the incentive inter-
vention that would enhance the probability that the
intervention would be sustained. As reflected in the bar-
riers to adoption, dedicated staff time and funding would
be essential to maintenance and should be secured prior
to a decision to adopt the intervention. In addition, both
staff and leadership interviews indicated that fully inte-
grating the intervention into the clinic would be essential
to maintenance. The intervention, as delivered during the
study, was viewed as a stand-alone intervention that was
the responsibility of specific individuals (in this case, re-
search staff ). While some individual staff members did re-
port utilizing information about patients’ progress in the
intervention in their therapeutic interactions, the patient
survey information would suggest that this was infrequent.
It does not seem that clinicians were uninterested or op-
posed to being more involved, as staff at both clinics pro-
vided unsolicited suggestions regarding ways that clinical
staff could be kept more up-to-date on patient progress in
the intervention. Therefore, it is more likely that they did
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incorporate information from the intervention into their
therapeutic interactions. This could be mitigated by
providing better education to all staff about the inter-
vention and by developing explicit expectations regard-
ing how staff should integrate information from the
intervention into their interactions with patients. An-
other option would be to have each case manager pro-
vide the incentive intervention to their case load rather
than assigning administration of the incentive interven-
tion to one or two isolated individuals. This option
would also eliminate the staff concern that patients were
attending their intervention appointments more regu-
larly then their clinical appointments as these would be
provided concurrently.
Evidence
Ratings on the ORCA indicated that staff at both facil-
ities generally agreed with the evidence supporting the
intervention, that the intervention met the needs of their
patients, and that the intervention fit with their treat-
ment philosophy. Staff interviews supported results from
the ORCA. The research log data also supported staff ’s
reported enthusiasm for the intervention with multiple
reports of clinical staff members assisting research staff
with recruitment and facilitating communication be-
tween research staff and study participants.
However, despite this general enthusiasm, there were
clear exceptions to this support with a small minority of
staff reporting a serious conflict between their personal
treatment philosophy and incentive interventions. They
strongly felt that the incentives created a “false”, external
motivation for abstinence that would undermine patients’
internal motivation for change and would interfere with
longer term treatment success. It is likely that these beliefs
are even more prevalent in community treatment settings
that do not have the strong focus on evidence-based prac-
tice currently promoted within the VHA system. While
these beliefs tend to be highly entrenched, having discus-
sions up front with staff and leadership to identify such
beliefs or concerns and to determine what types of evi-
dence staff would find compelling might encourage the
staff to consider supporting implementation. For example,
staff may simply not be aware of the level and detail of evi-
dence supporting incentive interventions. They also may
benefit from a more in-depth understanding of how be-
havioral reinforcements function in a variety of settings.
They may be encouraged by discussing incentive interven-
tions with other clinics that have already implemented or,
as suggested earlier, they may be willing to engage in a
brief test of incentive interventions in their own clinic that
would allow staff to see the benefits and risks of the
intervention among their own patients. The important
point is to engage the staff in a respectful discussionabout implementation early on so that their concerns
can be heard and addressed prior to a formal decision
to make a change in how they are going to treat their
patients. The Promoting Awareness of Motivational In-
centives (PAMI) website, based on knowledge gained
from the National Institute of Drug Abuse (NIDA) Clin-
ical Trials Network (CTN) Motivational Incentives for
Enhanced Drug Abuse Recovery study, provides several
excellent resources for staff education and training in-
cluding testimonial videos from patients and clinicians
regarding the impact of incentive interventions on clinic
culture and patient outcomes (http://www.bettertxoutcomes.
org/bettertxoutcomes/PAMI.html).
Context
ORCA survey results indicated that staff perceived a gen-
erally positive leadership/staff culture and positive leader-
ship practices. The ORCA survey supported interview
data, indicating that staff generally disagreed that they had
access to the necessary resources to support innovation.
Despite general agreement with the evidence support-
ing incentive interventions and contexts that support
innovation in general, the clinics involved in this study
perceived substantial barriers to implementation. The
implication is that barriers may be perceived as even
more substantial in sites that do not have these support-
ive characteristics. This highlights the importance of
conducting local assessment of Evidence and Context
when undertaking implementation efforts [43].
Limitations
One limitation of this study is that the ORCA was only
collected after the intervention had been running in the
clinic for 18 months. It would have been ideal to have
also collected this information prior to the start of the
intervention period, as experiencing the intervention
functioning in their clinic may have altered staff ’s atti-
tudes toward the intervention. Previous studies have in-
dicated that providers who have prior experience with
tangible incentive programs display more positive beliefs
about incentive programs and lower ratings of barriers
to adoption than those who report no experience with
such programs [44-46]. These findings reinforce the sug-
gestion, also made by other authors, that exposing treat-
ment providers to incentive programs through a pilot or
targeted demonstration may be a useful strategy for en-
couraging dissemination [47]. A second limitation was
that the sample size for the staff interviews was small,
particularly in site two, and therefore may not ad-
equately represent the opinions of the population of
clinic staff at the sites. Clinic staff that agreed to partici-
pate in the interviews may have had more positive opin-
ions about the intervention compared to those that
declined to be interviewed. Finally, because this was an
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tive intervention rather than an implementation trial with
the clinical staff conducting the intervention, staff percep-
tion of the intervention, particularly related to its impact
on workload, may be quite different than if they were re-
sponsible for conducting the intervention themselves.Conclusion
An implementation-focused process evaluation guided
by the RE-AIM and PARIHS frameworks led to signifi-
cant insights about the processes involved in implemen-
tation of incentive interventions and allowed us to
formulate concrete suggestions about implementation
strategies. Some of the most important insights were: 1)
the need to spend substantial effort on education and
persuasion strategies in sites where staff are skeptical of
the value of implementing incentive programs, and 2)
the need to assist leadership in developing strategies for
financing and staffing. Overall, the study demonstrates
the value of conducting implementation process evalua-
tions as a concurrent part of effectiveness research.
The goals of this paper were to describe an implemen-
tation-focused process evaluation conducted during a
randomized trial and distil findings into practical guid-
ance to others who wish to implement incentive inter-
ventions in substance use disorders clinics. Table 6
presents a summary of the key lessons learned from this
effort. It is our hope that this summary speaks to the
value of the effort expended on the process evaluation
and highlights issues to consider when attempting im-
plementation of an incentive intervention.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
HH conceived of the study, led the study design, interpreted data and
drafted the manuscript. CS participated in the study design, provided
extensive consultation on data interpretation, and provided critical revisions
to the manuscript. AB developed the data collection strategies, provided
database management, produced the demographic table and recruitment
figure, and provided comments on the manuscript. SN participated in study
design, performed statistical analyses, and provided comments on the
manuscript. MS participated in study design and provided critical revisions to
the manuscript. DK participated in study design and provided critical
revisions to the manuscript. All authors read and approved the final manuscript.Acknowledgments
This material is based on work supported by grant number IIR 03–120 from
the Department of Veterans Affairs, Veterans Health Administration, Office of
Research & Development, Health Services Research & Development. The
views expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the Department of Veterans
Affairs or the United States government. The authors would like to express
their gratitude to the following individuals for their contribution to this
study: Nancy Rettmann, Lee Ann Heim, Tabitha Leighton, Eliza McManus,
Evelina Marut, Alisha Baines Simon, Carl Isenhart, Brittney Hamilton, Tina
Marie Schmidt, Michelle Ingalsbe, and Carl Rimmele.Author details
1Veterans Health Administration Substance Use Disorder Quality
Enhancement Research Initiative, Minneapolis VA Healthcare System, One
Veterans Drive, Minneapolis, MN 55417, USA. 2Veterans Health Administration
Health Services Research and Development Center of Excellence,
Minneapolis VA Healthcare System, Minneapolis, MN 55417, USA. 3University
of Minnesota, Minneapolis, MN 55455, USA. 4Health Services Department,
Boston University School of Public Health; and Independent Consultant,
Amherst, MA 01002, USA. 5Johns Hopkins University School of Medicine,
Baltimore, MD 21224, USA. 6Center of Excellence in Substance Abuse
Treatment and Education, VA Puget Sound Healthcare System, Seattle, WA
98108, USA. 7University of Washington School of Medicine, Seattle, WA
98185, USA.
Received: 11 June 2013 Accepted: 2 December 2013
Published: 9 July 2014
References
1. Institute of Medicine: Crossing the quality chasm: a new health system for the
21st century. Washington D C: Institute of Medicine of the National
Academics Press; 2001.
2. Sung NS, Crowley WF Jr, Genel M, Salber P, Sandy L, Sherwood LM,
Johnson SB, Catanese V, Tilson H, Getz K, Larson EL, Scheinberg D, Reece
EA, Slavkin H, Dobs A, Grebb J, Martinez RA, Korn A, Rimoin D: Central
challenges facing the national clinical research enterprise. JAMA 2003,
289:1278–1287.
3. Rosenberg RN: Translating biomedical research to the bedside: a national
crisis and a call to action. JAMA 2003, 289:1305–1306.
4. Glasgow RE, Lictenstein E, Marcus AC: Why don’t we see more translation
of health promotion research to practice? rethinking the efficacy-to-
effectiveness transition. Am J Public Health 2003, 93:1261–1267.
5. Grol R, Wensing M, Eccles M: Improving patient care: the implementation of
change in clinical practice. Toronto: Elsevier; 2005.
6. Stetler CB, McQueen L, Demakis J, Mittman BS: An organizational
framework and strategic implementation for system-level change to
enhance research-based practice: QUERI Series. Implement Sci 2008, 3:30.
7. March JS, Siva SG, Compton S, Shapiro M, Califf R, Krishnan R: The case for
practical clinical trials in psychiatry. Am J Psychiatry 2005, 162:836–846.
8. Rubenstein LV, Pugh J: Strategies for promoting organizational and
practice change by advancing implementation research. J Gen Intern Med
2006, 21:S58–S64.
9. Stetler CB, Legro MW, Wallace CM, Bowman C, Guihan M, Hagedorn H,
Kimmel B, Sharp ND, Smith JL: The role of formative evaluation in
implementation research and the QUERI experience. J Gen Intern Med
2006, 21:S1–S8.
10. Stetler CB, Mittman BS, Francis J: Overview of the VA quality enhancement
research initiative (QUERI) and QUERI theme articles: QUERI series.
Implement Sci 2008, 3:8.
11. Hagedorn H, Hogan M, Smith JL, Bowman C, Curran GM, Espadas D, Kimmel
B, Kochevar L, Legro MW, Sales AE: Lessons learned about implementing
research evidence into clinical practice: experiences from VA QUERI.
J Gen Intern Med 2005, 21:S21–S24.
12. Wells KB: Treatment research at the crossroads: the scientific interface of
clinical trials and effectiveness research. Am J Psychiatry 1999, 156:5–10.
13. Tunis SR, Stryer DB, Clancey CM: Increasing the value of clinical research
for decision making in clinical and health policy. JAMA 2003,
290:1624–1632.
14. Proctor EK, Landsverk J, Aarons G, Chambers D, Glisson C, Mittman B:
Implementation research in mental health services: an emerging science
with conceptual, methodological, and training challenges. Adm Policy
Ment Health 2009, 36:24–34.
15. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C: Effectiveness-
implementation hybrid designs: combining elements of clinical
effectiveness and implementation research to enhance public health
impact. Med Care 2012, 50:217–226.
16. Oakley A, Strange V, Bonell C, Alleln E, Stephenson J, RIPPLE Study Team:
Process evaluation in randomized controlled trials of complex
interventions. BM J 2006, 332:413–416.
17. Campbell NC, Murray E, Darbyshire J, Emery J, Farmer A, Griffiths F, Guthrie
B, Lester H, Wilson P, Kinmonth AL: Designing and evaluating complex
interventions to improve health care. BMJ 2007, 334:455–459.
Hagedorn et al. Addiction Science & Clinical Practice 2014, 9:12 Page 15 of 15
http://www.ascpjournal.org/content/9/1/1218. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M:
Developing and evaluating complex interventions: the new medical
research council guidance. BMJ 2008, 337:979–983.
19. Hagedorn H, Noorbaloochi S, Baines Simon A, Bangerter A, Stitzer ML,
Stetler CB, Kivlahan D: Rewarding early abstinence in veterans health
administration addiction clinics. J Subst Abuse Treat 2013,
2013(45):109–117.
20. Glasgow RE, Vogt TM, Boyles SM: Evaluating the public health impact of
health promotion interventions: the RE-AIM framework. Am J Public
Health 1999, 89:1322–1327.
21. Glasgow RE, McKay HG, Piette JD, Reynolds KD: The RE-AIM framework for
evaluating interventions: what can it tell us about approaches to chronic
illness management? Patient Education & Counseling 2001, 44:119–127.
22. Gaglio B, Glasgow RE: Evaluation approaches for dissemination and
implementation research. In Dissemination and implementation research in
health: translating science into practice. Edited by Brownson R, Colditz G,
Proctor E. New York: Oxford University Press; 2012:327–356.
23. Rycroft-Malone J, Kitson A, Harvey G, McCormack B, Seers K, Titchen A,
Estabrooks C: Ingredients for change: revisiting a conceptual framework.
Qual Saf Health Care 2002, 11:174–180.
24. Rycroft-Malone J: The PARIHS framework: a framework for guiding the
implementation of evidence-based practice. J Nurs Care Qual 2004,
19:297–304.
25. Kitson A, Rycroft-Malone J, Harvey G, McCormack B, Seers K, Titchen A:
Evaluating the successful implementation of evidence into practice
using the PARIHS framework: theoretical and practical challenges.
Implement Sci 2008, 3:1.
26. Kessler RS, Purcell EP, Glasgow RE, Klesges LM, Bendeser RM, Peek CJ: What
does it mean to “employ” the RE-AIM framework? Evaluation and the
Health Professions 2013, 36:44–66.
27. Greenhalgh T, Robert G, Macfarlene F, Bate P, Kyriakidou O: Diffusion of
innovations in service organizations: systematic review and
recommendations. Milbank Q 2004, 82:581–629.
28. Simpson DD, Dansereau DF: Assessing organizational functioning as a
step toward innovation. NIDA Science & Practice Perspectives 2007, 3:20–28.
29. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC:
Fostering implementation of health services research findings into
practice: a consolidated framework for advancing implementation
science. Implement Sci 2009, 4:50.
30. Helfrich CD, Li YF, Sharp ND, Sales AE: Organizational readiness to change
assessment (ORCA): development of an instrument based on the
promoting action of research in health services (PARIHS) framework.
Implement Sci 2009, 4:38.
31. Hagedorn HJ, Heideman PW: The relationship between baseline
organizational readiness to change assessment subscale scores and
implementation of hepatitis prevention services in substance use
disorders treatment clinics. Implement Sci 2010, 5:46.
32. Miles MB, Huberman AM: Qualitative data analysis: an expanded sourcebook.
2nd edition. Thousand Oaks, CA: Sage Publications; 1994.
33. Katz EC, Robles-Sotelo E, Correia CJ, Silverman K, Stitzer ML, Bigelow G:
The brief abstinence test: effects of continued incentive availability
on cocaine abstinence. Experimental & Clinical Psychopharmacology 2002,
10:10–17.
34. Petry NM, Martin B, Simcic F Jr: Prize reinforcement contingency
management for cocaine dependence: integration with group therapy
in a methadone clinic. Journal of Consulting & Clinical Psychology 2005,
73:354–359.
35. Roll JM, Petry NM, Stitzer ML, Brecht ML, Peirce JM, McCann MJ, Blaine J,
MacDonald M, DiMaria J, Lucero L, Kellogg S: Contingency management for
the treatment of methamphetamine use disorders. Am J Psychiatr 2006,
163:1993–1999.
36. Silverman K, Robles E, Mudric T, Bigelow GE, Stitzer ML: A randomized
trial of long-term reinforcement of cocaine abstinence in methadone-
maintained patients who inject drugs. Journal of Consulting & Clinical
Psychology 2004, 72:839–854.
37. Higgins ST, Wong CJ, Badger GJ, Ogden DE, Dantona RL: Contingent
reinforcement increases cocaine abstinence during outpatient treatment
and 1 year of follow-up. J Consult Clin Psychol 2000, 68:64–72.
38. Petry NM, Alessi SM, Hanson T, Sierra S: Randomized trial of contingent
prizes versus vouchers in cocaine-using methadone patients. J Consult
Clin Psychol 2007, 75:983–991.39. Petry NM, Barry D, Alessi SM, Rounsaville BJ, Carroll KM: A randomized trial
adapting contingency management targets based on initial abstinence
status of cocaine-dependent patients. J Consult Clin Psychol 2012,
80:276–285.
40. Olmstead TA, Sindelar JL, Petry NM: Cost-effectiveness of prize-based
incentives for stimulant abusers in outpatient psychosocial treatment
programs. Drug Alcohol Depend 2007, 87:175–182.
41. Olmstead TA, Petry NM: The cost-effectiveness of prize-based and
voucher-based contingency management in a population of cocaine- or
opioid-dependent outpatients. Drug Alcohol Depend 2009, 102:108–115.
42. National Quality Forum: National voluntary consensus standards for the
treatment of substance use conditions: evidence-based treatment practices –
a consensus report. Washington, D.C: National Quality Forum; 2007.
43. Stetler CB, Damschroder LJ, Helfrich CD, Hagedorn HJ: A guide for applying
a revised version of the PARIHS framework for implementation.
Implement Sci 2011, 6:99.
44. Kirby KC, Carpenedo CM, Stitzer ML, Dugosh KL, Petry NM, Roll JM,
Saladin ME, Cohen AJ, Hamilton J, Reese K, Sillo GR, Stabile PQ, Sterling RC:
Is exposure to an effective contingency management intervention
associated with more positive provider beliefs? J Subst Abuse Treat 2012,
42:356–365.
45. Rash CJ, Petry NM, Kirby KC, Martino S, Roll J, Stitzer ML: Identifying
provider beliefs related to contingency management adoption using the
contingency management beliefs questionnaire. Drug Alcohol Depend
2012, 121:205–212.
46. Rash CJ, DePhilippis D, McKay JR, Drapkin M, Petry NM: Training
workshops positively impact beliefs about contingency management in
a nationwide dissemination effort. J Subst Abuse Treat 2013, 45(3):306–312.
47. Ducharme LJ, Knudsen HK, Abraham AJ, Roman PM: Counselor attitudes
toward the use of motivational incentives in addiction treatment.
Am J Addict 2010, 19:496–503.
doi:10.1186/1940-0640-9-12
Cite this article as: Hagedorn et al.: An implementation-focused process
evaluation of an incentive intervention effectiveness trial in substance use
disorders clinics at two Veterans Health Administration medical centers.
Addiction Science & Clinical Practice 2014 9:12.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
